Stock Events

Stock Events

Search...

Mind Medicine

€5.39

651

+€0.01+0.28% Today

Statistics

Day High

5.39

Day Low

5.39

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

474.13M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

13NovExpected

Q4 2023

Q1 2024

Q2 2024

Next

-1.06

-0.73

-0.4

-0.07

Expected EPS

-0.2533972

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MMQ.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Compass Pathways

Compass Pathways operates in the psychedelic medicine space, focusing on psilocybin therapy for depression, directly competing with Mind Medicine's psychedelic-based treatments.

ATAI Life Sciences N.V.

ATAI Life Sciences is a biotech company with a focus on psychedelic and non-psychedelic compounds for mental health, making it a direct competitor in the psychedelic medicine market.

GH Research is developing a novel therapeutic approach for mental health disorders using 5-MeO-DMT, competing in the same space as Mind Medicine's psychedelic-based treatments.

Cybin Inc. is working on psychedelic therapeutics for psychiatric and neurological conditions, directly competing with Mind Medicine in the development of psychedelic-based treatments.

Revive Therapeutics

Revive Therapeutics is exploring the use of psychedelics for the treatment of mental illness and addiction, competing in the same therapeutic space as Mind Medicine.

Red Light Holland is focused on the production, growth, and sale of a premium brand of magic truffles, entering the broader market of psychedelic substances that Mind Medicine is also targeting.

Mydecine Innovations

Mydecine Innovations Group is a biotech company focusing on the development of psychedelic therapies, making it a competitor in the emerging field of psychedelic medicine.

About

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Show more...

CEO

Mr. Robert Barrow

Employees

57

Country

CA

ISIN

CA60255C8850

WKN

000A3DR6E

Listings